The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer.
A. Gropper
No relevant relationships to disclose
H. J. Burstein
No relevant relationships to disclose
L. Harris
No relevant relationships to disclose
K. S. Anderson
No relevant relationships to disclose
J. M. Gold
No relevant relationships to disclose
W. J. Younger
No relevant relationships to disclose
C. A. Bunnell
No relevant relationships to disclose
J. S. Najita
No relevant relationships to disclose
E. P. Winer
No relevant relationships to disclose
E. L. Mayer
No relevant relationships to disclose